

AD_____

Award Number: DAMD17-01-1-0282

TITLE: Dissecting the Mechanism of T Cell Tolerance for More
Effective Breast Cancer Vaccine Development

PRINCIPAL INVESTIGATOR: Brian H. Ladle
Elizabeth M. Jaffee, M.D.

CONTRACTING ORGANIZATION: Johns Hopkins University
Baltimore, Maryland 21205

REPORT DATE: August 2004

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050715 094

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 2004	3. REPORT TYPE AND DATES COVERED Annual Summary (15 Jul 2001 - 14 Jul 2004)	
4. TITLE AND SUBTITLE Dissecting the Mechanism of T Cell Tolerance for More Effective Breast Cancer Vaccine Development			5. FUNDING NUMBERS DAMD17-01-1-0282	
6. AUTHOR(S) Brian H. Ladle Elizabeth M. Jaffee, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Johns Hopkins University Baltimore, Maryland 21205 <i>E-Mail:</i> bladle@jhmi.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) T cell tolerance to tumor-associated antigens is a significant barrier to immune based treatments of human cancers. One such tumor-associated antigen is the proto-oncogene <i>HER-2/neu (neu)</i> which is overexpressed in 35-40% of all human breast cancers. Although patients with neu expressing tumors develop antibody and T cell responses to this antigen, these responses are weak and unable to hinder tumor growth. Our work has focused on understanding these mechanisms of T cell tolerance using the <i>neu-N</i> transgenic mice that express the wild type rat <i>neu</i> cDNA under control of the MMTV promoter. Since neu is an endogenously expressed antigen, profound neu-specific immune tolerance exists in the <i>neu-N</i> mice. We have characterized the immunodominant T cell epitope of neu recognized by parental FVB/N mice, RNEU₄₂₀₋₄₂₉. Studying T cell responses to this epitope has yielded important insights into the mechanisms of tolerance in the <i>neu-N</i> mice. Following a neu-targeted vaccine, 100% of FVB/N mice will activate T cells specific to RNEU420-429, whereas RNEU420-429-specific T cells are not activated in the <i>neu-N</i> mice. However, if vaccine is combined with immunomodulatory doses of chemotherapy in <i>neu-N</i> mice, RNEU420-429-specific are now activated in a subset of transgenic mice. Employing MHC tetramer technology, adoptive transfer of RNEU420-429-specific T cells, and T cell activation assays, we have begun to understand the mechanisms of tolerance that prevent the induction of protective immunity against tumors in the <i>neu-N</i> mice and ways to circumvent them. These findings are the basis for a Phase I Clinical Trial now underway at our institution.				
14. SUBJECT TERMS Immunology, murine T cell tolerance, cancer immunotherapy				15. NUMBER OF PAGES 25
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	14
Reportable Outcomes.....	14
Conclusions.....	15
References.....	16
Appendices.....	18

Brian H. Ladle
Phone: 410-614-1772
Fax: 410-614-8216

Address:
CRB 4M06, 1650 Orleans Street
Baltimore, MD 21231

Introduction

In humans, the proto-oncogene *HER-2/neu* (*neu*) is overexpressed in 35-40% of all breast cancers (1). Although patients with neu expressing tumors develop antibody and T cell responses to this antigen, these responses are weak and unable to hinder tumor growth. This suggests that T cell tolerance is a significant barrier to immune based treatments that target neu and most likely other antigens expressed by breast cancers. *HER-2/neu* (*neu-N*) transgenic mice express the wild type rat *neu* cDNA under control of the MMTV promoter (2). Female mice spontaneously develop focal mammary tumors which overexpress the transgene in a stochastic manner starting approximately at 4 months of age. Since neu is an endogenously expressed antigen, it is likely that neu-specific immune tolerance exists in the *neu-N* mice. Three findings strongly support the existence of neu-specific tolerance in these mice. First, subcutaneous injection of 100-fold less transplantable *neu*-expressing mammary tumors is required for tumor growth in the *neu-N* mice when compared with the parental FVB/N mice. Second, neu-specific vaccines designed to prevent tumor development provide long-term prevention of *neu*-expressing tumors in the FVB/N mice but only delay slightly tumor growth in the *neu-N* mice. Third, neu-specific CD8⁺ T cells (CTL) derived from FVB/N mice can lyse neu-expressing mammary tumors much more effectively than T cells derived from *neu-N* mice. (3) Based on these findings, the *neu-N* transgenic mouse model of mammary tumors provides a clinically relevant model for developing vaccines that overcome tumor tolerance. The overall aim of this work is to determine the mechanisms by which immune tolerance of CTL inhibits effective immunization in the *neu-N* transgenic mice and discover ways to circumvent them to increase the effectiveness of cancer vaccines.

Body

Identification of specific HER-2/neu MHC class I peptide epitopes

To study the mechanisms of CD8⁺ T cell tolerance to neu in the *neu-N* mice, we first identified an immunodominant, MHC class I restricted T cell epitope from the neu protein. This research is described in detail in the attached manuscript in the appendix from the *Journal of Immunology* (*J. Immunology*, 2003, 170: 4273-4280). Briefly, neu-specific T cell lines were generated from vaccinated FVB/N mice by repeated *in vitro* stimulation with neu-expressing target cells. T cell lines, determined to be neu-specific by *in vitro* lysis assays, were then screened for activity against 9 cell lines, each expressing a fragment of the whole neu protein. Several T cell lines were activated by fragment 4 of neu. The T cell lines were then screened for activity against overlapping 10-mer peptides spanning the sequence of fragment 4. Each line reacted to the 10-mer comprising amino acids 420-429 (PDSLRLDSVF) of neu. We also determined that RNEU₄₂₀₋₄₂₉ is naturally processed and presented by tumor cells and is the optimal epitope in comparison to 8- and 9-mer derivatives.


We also generated T cell lines from *neu-N* mice given a neu targeted vaccine. Although multiple neu-specific lines were grown, only one recognized RNEU₄₂₀₋₄₂₉. Significant efforts have been made to identify other neu T cell epitopes recognized by the other T cell lines. The method described to identify the RNEU₄₂₀₋₄₂₉ epitope was unsuccessful. None of the *neu-N*-derived T cell lines recognized any of the 9 neu fragments. A combinatorial peptide library was also screened with the *neu-N* derived T cells employing a method others have used to discover T

cell epitopes (4). Again, after several attempts, no T cell epitopes could be determined from the data. We are continuing efforts to discover other neu T cell epitopes by utilizing bone-marrow derived dendritic cells that are infected with recombinant *Listeria* that express fragments of neu. We are also undertaking a large peptide synthesis approach where we are synthesizing overlapping 10-mers across the whole neu sequence.

Upon further study, we have shown by *ex vivo* analysis of T cell activation that all FVB/N mice given a neu-targeted vaccine generate RNEU₄₂₀₋₄₂₉-specific T cells, whereas RNEU₄₂₀₋₄₂₉-specific T cells are rarely observed in *neu*-N mice given the same vaccine. Hypothesizing that functional T cell tolerance to RNEU₄₂₀₋₄₂₉ in the *neu*-N mice could be one of the main mechanisms preventing effective anti-tumor immunity, we invested a significant amount of time and resources in developing reagents to study RNEU₄₂₀₋₄₂₉-specific T cell responses.

Construction of H2-D^a RNEU₄₂₀₋₄₂₉ dimer and tetramer


To study the T cell Receptor (TCR)/MHC class I/peptide interaction of RNEU₄₂₀₋₄₂₉-specific T cells, a MHC class I dimer loaded with RNEU₄₂₀₋₄₂₉ was made according to established protocols (5). Specific staining of RNEU₄₂₀₋₄₂₉-specific T cells was observed (data not shown), however the dimer reagent did not provide the sensitivity to detect T cell populations *ex vivo* nor could be used to estimate T cell receptor avidity. MHC tetramers have been shown to provide much cleaner staining of T cell lines and can detect T cells specific to the bound peptide epitope directly *ex vivo*. Tetramer has also been used to study the avidity of TCR/MHC/peptide interactions. Because of these issues, we chose to not use the MHC dimer, but instead we made a H2-D^a-RNEU₄₂₀₋₄₂₉ Tetramer. Specific staining of the RNEU₄₂₀₋₄₂₉-specific T cell lines (**Figure 1a**) was observed as well detection of RNEU₄₂₀₋₄₂₉-specific T cell populations *ex vivo* following a single *in vitro* stimulation (**Figure 1b**).




Analysis of T cell peptide epitopes for MHC class I binding affinity

Affinity for peptide epitopes for its cognate MHC class I molecule impacts how it is presented by antigen presenting cells (APC) and how well the TCR interacts with the APC. Several methods are available to test binding affinity. Surface plasmon resonance gives very precise measurements of binding affinities, yet is very labor intensive. As our intent is to simply determine which epitopes would be most effectively presented to T cells, we decided to use assays that give a more functional readout of peptide binding as opposed to a precise binding constant. We first determined the optimal peptide length of RNEU₄₂₀₋₄₂₉ for binding to MHC I. A T2 cell binding assay was performed on the peptides of interest. T2 cells lack the TAP transporter and as a result cannot present endogenous peptides on MHC I. The lack of peptide

causes the MHC to be unstable and be quickly internalized and degraded. Peptide binding can be assayed by incubating the T2 cells in serum free media containing the peptide of interest and then staining for MHC class I. Cells are then fixed and analyzed by flow cytometry. The level of MHC I expression is measured and will be highest on cells incubated with the peptide that binds to MHC I the best. We transfected T2 cells with murine H2-D^q to assay the binding of new peptide epitopes. 8-mer and 9-mer variants covering RNEU₄₂₀₋₄₂₉ were assayed. **Figure 2** plots the mean fluorescence intensity of MHC I staining after the T2-D^q cells were incubated with different peptides. The 10-mer RNEU₄₂₀₋₄₂₉ was determined to be the optimal length for binding to H2-D^q.




It was also noted that if the terminal phenylalanine at position 10 was removed no binding was observed, indicating its role as perhaps a crucial anchor residue for peptides in H2-D^q. To further investigate the role of each residue for MHC binding, alanine substitutions at each position were made and binding to T2-D^q cells was measured (**Figure 3**). When alanine was substituted at positions 4 and 10 of RNEU₄₂₀₋₄₂₉, binding to T2-D^q cells was abolished. These results indicate that the leucine at position 4 and the phenylalanine at position 10 are critical for binding to H2-D^q and serve as anchor residues for binding in the peptide binding groove of H2-D^q. The position of the anchor residues for H2-D^q has not previously been reported.




The second assay used to study peptide binding is an *in vitro* lysis assay employing T cells specific to the peptide epitopes being tested. Target cells, in our case T2-D^q cells, are pulsed with serial dilutions of each peptide and labeled with ⁵¹Cr. The targets are then incubated with the T cells and, after 4 hours, lysis of the targets is measured by determining the level of ⁵¹Cr in each sample. Peptides with higher binding affinities will cause increased lysis at lower concentrations. The results of these assays are included in the next section as we used the assay to determine variants of RNEU₄₂₀₋₄₂₉ that bind to H2-D^q with higher affinity.

Create amino acid substitutions in RNEU₄₂₀₋₄₂₉ to generate a more immunogenic peptide

Other systems have shown that T cell epitopes can be rendered more immunogenic by varying the peptide to bind more tightly to MHC I (6). As tolerance to RNEU₄₂₀₋₄₂₉ in *neu*-N mice appears to contribute to the lack of effective antitumor immunity, we searched for altered peptide analogues of the immunodominant neu peptide that had enhanced immunogenicity in our system. Altered forms of RNEU₄₂₀₋₄₂₉ were created by substituting alanine at each of the 10 positions. This type of approach has been successful in identifying heteroclitic T cell peptides in both rodent and human settings (6). In the majority of cases, substitutions did not enhance recognition. However, when alanine was substituted for glutamate at position 2, this peptide (designated RNEU₄₂₀₋₄₂₉A2) demonstrated markedly improved recognition by a FVB/N-derived T cell clone in the lysis assay described above as compared with wild-type peptide (**Figure 4**).



To determine if this heteroclitic peptide can immunize mice against mammary tumor expressing the natural RNEU₄₂₀₋₄₂₉ epitope, both wild-type RNEU₄₂₀₋₄₂₉ and the heteroclitic variant RNEU₄₂₀₋₄₂₉A2 were used to vaccinate mice. Dendritic cells derived from FVB/N mice were pulsed *in vitro* with either of these peptides (or with an irrelevant peptide) and then injected subcutaneously into FVB/N and *neu*-N mice followed by a subcutaneous challenge with the *neu*-expressing mammary tumor line NT2. As shown in **Figure 5**, mice immunized with dendritic cells pulsed with the wild-type peptide developed tumor at about the same rate as mice immunized with an irrelevant peptide ($p < 0.15$ for FVB/N mice, $p < 0.39$ for *neu*-N mice). However, FVB/N mice immunized with the heteroclitic peptide showed a lag in tumor growth as compared to FVB/N mice immunized with the irrelevant peptide (**A**, $p < 0.012$). Although not statistically significant, *neu*-N mice demonstrated a promising trend toward protection when vaccinated with the heteroclitic peptide (**B**, $p < 0.21$).

Figure 5.

Determine avidity of RNEU₄₂₀₋₄₂₉-specific T cells for MHC/peptide complex


Several reports looking at TCR avidity to self antigens found that mechanisms of tolerance delete the CD8⁺ T cells expressing the highest avidity TCR to self antigens, leaving only low avidity T cells that can be activated against a self antigen (7). If this is the case, tumor vaccines might only activate low avidity T cells specific for a tumor antigen that are poorly lytic and ineffective at eradicating tumor. Attempts to improve tumor vaccines could then focus on increasing the activity or quantity of these low avidity T cells. One such approach is vaccinating with a heteroclitic epitope as discussed above.

Another approach to improving vaccine efficacy that our lab has pioneered is combining vaccine with immunomodulatory doses of chemotherapy. Combining the granulocyte macrophage colony stimulating factor (GM-CSF)-secreting vaccine with cyclophosphamide (Cy) given 1 day before vaccine (100 mg/kg) and doxorubicin (Dox) given 7 days after vaccine (5 mg/kg) improves long term tumor free survival in *neu-N* mice to 20-30% as opposed to 0% long term survival in groups given vaccine alone or mock vaccine plus chemotherapy (8). Upon analysis of the T cell response generated in the vaccine + chemotherapy treated *neu-N* mice, RNEU₄₂₀₋₄₂₉-specific T cells were only found in mice that remained tumor free and never in mice where tumors grew out (data not shown). We wanted to test whether or not the T cells activated in the vaccine + chemotherapy treated mice were low avidity T cells that had been rendered more active by the chemotherapy or if the chemotherapy somehow allowed high avidity T cells for RNEU₄₂₀₋₄₂₉ to become activated.

Three RNEU₄₂₀₋₄₂₉-specific T cell lines were analyzed for TCR avidity using the H2-D^bRNEU₄₂₀₋₄₂₉ tetramer described above: 1. T cell line derived from vaccinated FVB/N mice 2. T cell line from *neu-N* mice given vaccine alone and 3. T cell line from *neu-N* mice that had remained tumor free following vaccine + chemotherapy. Each T cell line was shown to be uniformly reactive to RNEU₄₂₀₋₄₂₉ by intracellular cytokine staining following peptide stimulation (data not shown). The TCR and CD8 expression level of each line was also determined and shown to be equivalent (data not shown). Next each line was stained with increasing dilutions of tetramer (Figure 6). The cells were fixed and intensity of tetramer staining was analyzed by flow cytometry. If the T cell lines express equivalent levels of TCR, then tetramer staining intensity at each dilution will directly correlate with the strength of interaction between the TCR and the peptide/MHC complex. High avidity T cell lines will maintain higher tetramer staining levels at low tetramer concentrations, whereas a low avidity T

cell line will stain very poorly at low tetramer concentrations. The FVB/N line (Figure 6a) and the *neu*-N + chemotherapy line (Figure 6c) still showed a shift in tetramer staining at a 1:500 dilution, whereas the *neu*-N line (Figure 6b) showed no shift after the 1:5 dilution. From this data, it appears that the T cell line from the *neu*-N mice given chemotherapy is a high avidity T cell, despite being specific to an endogenous self antigen.

Figure 6.




As this data contradicts findings in other models where only low avidity T cells to self antigens can be activated, we sought additional data to confirm these results. A “tetramer fall-off” assay was designed to determine the binding affinity of the TCR/MHC/peptide complex. Cells were first shown to have equivalent TCR expression levels. The lines were then stained with tetramer at the 1:5 dilution and excess tetramer was removed with two washes. Antibody to MHC I was then added in 20 molar excess and the samples were then assayed for tetramer staining level at time points up to four hours. Tetramer dissociates from the T cell according to the off-rate of the TCR/MHC/peptide complex and will then be bound up by the excess antibody to MHC I. The tetramer signal decreases over time according to the off-rate. These values were plotted and the off- rate was determined as the average of three independent experiments for each T cell line (Table 1). The low off-rates of the FVB/N and *neu*-N + chemotherapy lines compared to the *neu*-N line provide additional evidence that in the *neu*-N mice high avidity T cells to self antigen exist and be activated to the self antigen.

Table 1. k_{off} for RNEU₄₂₀₋₄₂₉-specific T Cell Lines

T cell line	k_{off} (min^{-1})	Stdev
FVB/N	41.5×10^{-3}	$\pm 10.1 \times 10^{-3}$
<i>neu</i> -N	272.7×10^{-3}	$\pm 164.1 \times 10^{-3}$
<i>neu</i> -N + chemotherapy	17.5×10^{-3}	$\pm 3.9 \times 10^{-3}$

As the possibility exists that the results seen with the T cell lines are simply an artifact of long term culture, we next sought to confirm the data obtained from the T cell lines with experiments looking at the T cell response in the *neu*-N mice after only one *in vitro* peptide stimulation. *neu*-N mice were given a NT tumor challenge followed by vaccine + chemotherapy as described above. The spleens from *neu*-N mice that remained tumor free (6 of 42 mice), 3 tumor bearing *neu*-N mice, and 2 vaccinated FVB/N mice were harvested and stimulated for 7 days with RNEU₄₂₀₋₄₂₉. On day seven, CD8⁺ T cells were enriched from the *in vitro* culture and stained for CD8, CD62L, and with increasing dilutions of tetramer. Cells were fixed and analyzed by flow cytometry. Events were gated on CD8⁺, CD62L^{lo} cells and tetramer staining intensity was compared between mice. **Figure 7** shows the plots from three representative mice. Despite mouse to mouse variability, when comparing CD8⁺ T cells from tumor free *neu*-N mice given chemotherapy and FVB/N mice, both contained high avidity RNEU₄₂₀₋₄₂₉-specific T cells.




Our data from the *neu*-N mice suggest a model of tolerance where a spectrum of low avidity to high avidity T cells specific to self antigens (e.g. tumor antigens) exist in the periphery, yet if vaccine alone is given only the low avidity T cells are activated. However, if vaccine is combined with immunomodulatory treatments (e.g. the chemotherapy regimen we have described) the high avidity T cells can be activated and provide a potent antitumor effect. This represents a major paradigm shift in trying to improve the efficacy of tumor vaccines. As opposed to attempts to make low avidity T cells more active, understanding the mechanisms of tolerance that prevent the activation of the high avidity tumor-reactive T cells will yield even more effective vaccines. We have focused on adoptive transfer experiments both to track the fate

of RNEU₄₂₀₋₄₂₉-specific T cells in the *neu*-N mice and to understand the mechanisms of tolerance that prevent the high avidity T cells from being activated.

Adoptive transfer of T cells from FVB/N and neu-N mice to evaluate their ability to cure pre-established mammary tumors

Having established the relative avidity for RNEU₄₂₀₋₄₂₉ of the three T cell lines from FVB/N, *neu*-N (referred to as low avidity *neu*-N), and *neu*-N + chemotherapy (referred to as high avidity *neu*-N), we performed adoptive transfer experiments to determine their effectiveness against *neu* expressing tumors *in vivo*. An influenza hemagglutinin-specific T cell line was used as a negative control (HA T cell line). The T cells were cultured and 1×10^7 cells were transferred into mice that had been challenged with tumor three days previously. Mice were monitored twice weekly for tumor growth. The mice were given twice daily injections until the completion of the experiment of interleukin 2 (IL-2). Four groups of mice were studied: 1. FVB/N (Figure 8a) 2. FVB/N given 100 mg/kg Cy the day before transfer (Figure 8b) 3. *neu*-N (Figure 8c) 4. *neu*-N mice given 100 mg/kg Cy the day before transfer (Figure 8d).



This *in vivo* data is surprising in part when compared to the *in vitro* data using the same cells. We hypothesized that the *neu*-N high avidity line would be more effective *in vivo* when compared to the *neu*-N low avidity line. However, the results showed the exact opposite effect. The low avidity line was effective in the FVB/N mice and delayed tumor growth the *neu*-N mice. The *neu*-N high avidity line did not even protect the FVB/N mice from tumor. We hypothesize that the differences of the *in vitro* to *in vivo* effect are due to the fact that they are T cell lines that have been grown in long-term culture. Differences in growth properties, sensitivity to growth factors, or other factors caused by culture could explain the differences. We are continuing to


study the differences in these T cell lines by microarray analysis in the hopes of being able to better explain the differences in activity. Thus, as other confounding variables seem to be at play in the adoptive transfer experiments using the T cell lines, we have shifted the focus of our *in vivo* studies to using CD8⁺ T cells directly from vaccinated mice that have not been cultured.

Tracking and functionality of adoptively transferred congenic T cells

We had initially hoped to be able to track transferred T cells using the H2-D^aRNEU₄₂₀₋₄₂₉ dimer or tetramer. This, however, proved to not be technically feasible. The dimer has very poor sensitivity and the tetramer is also not sensitive enough to track small populations without needing an *in vitro* peptide stimulation first. We also used Green Fluorescent Protein transduced T cell lines to track the T cells following transfer. Although the sensitivity was good enough to detect very few cells (data not shown), they could only be used for short term experiments as GFP is immunogenic and the mouse would mount an immune response against the transferred cells. The GFP T cells are also T cell lines and the problems discussed above with *in vivo* experiments would persist.

A marker used by many models is Thy1 (CD90). It is a membrane protein expressed at high levels on all T cells and two alleles exist (Thy1.1 and Thy1.2) that differ by only one amino acid. High quality antibodies are available that can distinguish between the two alleles. FVB/N mice express Thy1.1 so we performed backcrosses (10 generations) with Balb/c mice (expressing Thy1.2) to breed the Thy1.2 marker onto the FVB/N background. We can now use the FVB/N Thy1.2 mice as a source of T cells that can be easily tracked and analyzed after transfer into FVB/N or *neu*-N mice.


The first experiment was to determine the fate of high avidity T cells from FVB/N mice in *neu*-N mice. FVB/N Thy1.2 mice were vaccinated, generating high avidity RNEU₄₂₀₋₄₂₉ specific T cells. Two weeks after vaccine, CD8⁺ T cells were purified from FVB/N Thy1.2 mice and 4x10⁶ CD8⁺ T cells were transferred into FVB/N or *neu*-N mice that had been vaccinated earlier in the day. Two weeks after transfer, spleens were harvested and the activity of CD8⁺ T cells to RNEU₄₂₀₋₄₂₉ was assayed by intracellular cytokine staining for interferon gamma (IFN- γ). Cells were stained for Thy1.2 (Thy1.2⁺ cells = transferred cells, Thy1.2⁻ cells = host cells), CD8, and IFN- γ . **Figure 9** shows representative results from FVB/N mice (**Figure 9a**) and *neu*-N mice (**Figure 9b**) given vaccine and transfer of Thy1.2 T cells. The effector RNEU₄₂₀₋₄₂₉-specific Thy1.2 T cells proliferated and produced IFN- γ after transfer into the FVB/N host. However, the same T cells transferred into the *neu*-N mice were deleted, suppressed, or inactivated, as no IFN- γ -producing Thy1.2⁺ T cells were observed. This finding suggests that mechanisms exist in the *neu*-N mice that do not simply prevent the activation of high avidity RNEU₄₂₀₋₄₂₉-specific T cells but can also inhibit the activity of previously activated T cells. We are currently investigating the cell type or factor that prevents the activation of these cells in the *neu*-N mice that is not present in the FVB/N mice.



Characterizing cells that prevent the activation of high avidity RNEU₄₂₀₋₄₂₉-specific T cells


As we have shown that high avidity T cells to the neu self antigen can exist in *neu*-N mice, why these T cells are not activated by vaccine alone, but can be activated by vaccine + chemotherapy remains one of the most important questions. One hypothesis is that regulatory T cells (T_{regs}), which have been shown to play an important role in preventing autoimmunity (9), inhibit the activation of the high avidity T cells. A subset of CD4⁺ T cells that express CD25 have been shown to act as T_{regs} in several models (10). We hypothesized that this T cell subset might be suppressing the activation of the high avidity T cells and preventing effective antitumor immunity.

To test this hypothesis, *neu*-N mice were given vaccine + chemotherapy followed by tumor challenge two weeks after vaccine. One day prior to tumor challenge, groups of the *neu*-N mice received adoptively transferred T cell subsets from *neu*-N mice that received tumor and vaccine alone. If chemotherapy deleted or inhibited T_{regs}, then the adoptive transfer could restore the T_{regs} and inhibit the antitumor response. If the T cell subset adoptively transferred did not contain T_{regs}, then tumor free mice would still be observed. **Figure 10** shows the results of transferring CD8⁺ T cells (**Figure 10a**), CD4⁺CD25⁻ T cells (**Figure 10b**), or CD4⁺CD25⁺ T cells (**Figure 10c**). Only transferring the CD4⁺CD25⁺ subset resulted in suppressing the antitumor immune response.



As CD4⁺CD25⁺ T cells in *neu*-N mice are able to inhibit the antitumor response in *neu*-N mice given vaccine + chemotherapy, we wanted to see if they could inhibit the immune response in FVB/N mice where no other mechanisms of tolerance to neu should be present. *neu*-N mice were given tumor challenge followed by vaccine. Two weeks later the CD4⁺CD25⁺ T cells were purified and 5x10⁵ T_{regs} were transferred into the FVB/N mice which were then vaccinated. Two weeks later the CD8⁺ T cell response to RNEU₄₂₀₋₄₂₉ was determined in the FVB/N mice given transferred cells. As seen in **Figure 11**, the mice given CD4⁺CD25⁺ T cells from *neu*-N mice had significantly fewer ($p=0.016$) RNEU₄₂₀₋₄₂₉-specific T cells as determined by intracellular staining for IFN- γ . Although T_{reg} transfer decreased the immune response in FVB/N mice, T_{regs} did not completely inhibit the immune response to RNEU₄₂₀₋₄₂₉. As no response to RNEU₄₂₀₋₄₂₉ is seen in *neu*-N mice given vaccine alone, this indicates that although T_{regs} must be playing a role in *neu*-N mice, other factors are also at play that prevent an effective antitumor immune response.

Figure 11.



Key Research Accomplishments

- Characterized the immunodominant MHC I restricted epitope of rat HER-2/neu in the FVB/N mice – RNEU₄₂₀₋₄₂₉.
- Determined the anchor residues for epitope binding to H2-D^a to be amino acids 4 and 10.
- Generated an altered, more immunogenic version of RNEU₄₂₀₋₄₂₉ → RNEU₄₂₀₋₄₂₉A2.
- Demonstrated that vaccination of both parental and transgenic mice with the altered peptide resulted in improved tumor protection over vaccination with wild-type version.
- Generated the H2-D^aRNEU₄₂₀₋₄₂₉ Tetramer.
- By tetramer analysis, determined the relative avidity of the three RNEU₄₂₀₋₄₂₉-specific T cell lines – vaccinated FVB/N, vaccinated *neu*-N, and vaccine + chemotherapy *neu*-N.
- Determined that high avidity RNEU₄₂₀₋₄₂₉-specific T cells can be activated in *neu*-N mice if given vaccine + chemotherapy.
- Using adoptive transfer of congenic T cells, demonstrated that *neu*-N mice can actively suppress/inhibit high avidity FVB/N-derived RNEU₄₂₀₋₄₂₉-specific effector T cells.
- Characterized the CD4⁺CD25⁺ subset of T cells from *neu*-N mice as able to suppress the immune response in chemotherapy treated *neu*-N mice and non-tolerant FVB/N mice.

Reportable Outcomes

Bibliography

- **Ercolini, A.M., Machiels, J.P., Chen, Y.C., Slansky, J.E., Giedlen, M., Reilly, R.T., and Jaffee, E.M.** Identification and Characterization of the Immunodominant Rat HER-2/neu MHC Class I Epitope Presented by Spontaneous Mammary Tumors from *HER-2/neu*-Transgenic Mice. *The Journal of Immunology*, 2003, 170: 4273-4280.
- **A.M. Ercolini, B.H. Ladle, E.A. Manning, L.W. Pfannenstiel, T.D. Armstrong, J-P.H. Machiels, J.G. Bieler, L.A. Emens, R.T. Reilly, and E.M. Jaffee.** Recruitment of latent pools of high avidity CD8⁺ T cells to the anti-tumor immune response. (manuscript in preparation)
- **Anne M. Ercolini.** Dissecting the mechanisms of CD8⁺ T cell tolerance to the proto-oncogene *HER-2/neu* in the *HER-2/neu* transgenic mouse model of mammary cancer. Dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy. Baltimore, MD. February 2003.

- **B.H. Ladle, A.M. Ercolini, E.A. Manning, L.W. Pfannenstiel, T.D. Armstrong, J-P.H. Machiels, J.G. Bieler, L.A. Emens, R.T. Reilly, and E.M. Jaffee.** Recruitment of latent pools of high avidity CD8⁺ T cells to the anti-tumor immune response. 12th Annual SPORE Investigator's Workshop – National Cancer Institute. July 10-13, 2004. Baltimore, MD. Abstract #226. Poster and Talk Presentation.
- **B.H. Ladle, E.A. Manning, A.M. Ercolini, L.A. Emens, E.M. Jaffee.** Regulatory T cells play an active role in preventing a productive, high-avidity CD8⁺ T cell response against HER-2/neu in the *HER-2/neu* transgenic mouse. Keystone Symposia on Regulatory/Suppressor T Cells, Banff, Alberta, Canada. March 10-15, 2004. Abstract #334. Poster Presentation.
- **Ercolini, A.M., Armstrong, T., Ladle, B.H., Machiels, J.P., Lei, R.Y., Reilly, R.T. and Jaffee, E.M.** An alternate, lower-affinity neu-specific T cell repertoire in *HER-2/neu* transgenic mice relative to the parental strain may explain neu-specific tolerance to neu-expressing tumors. Keystone Symposia on Basic Aspects of Tumor Immunology, Keystone, CO, Feb. 2003. Abstract #318. Poster Presentation.
- **Ladle, B.H., Manning, E.M., Emens, L.A., Ercolini, A.M., Machiels, J.P., Jaffee, E.M.** Reversal of CD8⁺ peripheral tolerance in the *HER-2/neu* transgenic mice by deletion of CD4⁺CD25⁺ regulatory T cells. Keystone Symposia on Basic Aspects of Tumor Immunology, Keystone, CO, Feb. 2003. Abstract #333. Poster Presentation.
- **Ercolini, A.M., Armstrong, T.D., Ladle, B.H., Machiels, J.P., Lei, R., Reilly, R.T., and Jaffee, E.M.** Presentation at New Investigators' Luncheon entitled "Dissecting the mechanisms of T cell tolerance for more effective breast cancer vaccine development." Department of Defense Breast Cancer Research Program Meeting, Orlando, FL, September 28, 2002. Abstract#P54-12.

Degrees/Employment

- Doctorate of Philosophy Degree in Immunology from The Johns Hopkins University School of Medicine awarded to **Anne M. Ercolini** in February 2003.
- Post-Doctoral Research Fellow – Position obtained by **Anne M. Ercolini** in March 2003 in the laboratory of Stephen D. Miller, Department of Microbiology-Immunology and Interdepartmental Immunobiology Center, Northwestern University Medical School, 303 E. Chicago Avenue, Chicago, IL 60611

Research Reagents

- GFP-expressing RNEU₄₂₀₋₄₂₉-specific T cell line
- H2-D^a-RNEU₄₂₀₋₄₂₉ MHC Tetramer
- FVB/N Thy1.2 congenic mice

Persons Receiving Salary Support

- Anne M. Ercolini, Ph.D. (July 2001 – March 2003)
- Brian H. Ladle, candidate for M.D./Ph.D. (March 2003 – July 2004)

Conclusions

Although the presence of antigen-specific CTL has been demonstrated in patients with tumor, the responses for the most part are weak and unable to hinder the growth of the malignancy. This has been shown in many types of cancer including neu-specific T cells in breast cancer. In some instances this may be due to an ineffective vaccine approach. However,

in many cases mechanisms of peripheral T cell tolerance to specific tumor antigens may be at work. A major goal of cancer research is to develop therapies that will reverse the tolerant state and allow T cells to more effectively respond to tumor. *neu*-N transgenic mice display tolerance to the endogenous *neu* transgene and are therefore a clinically relevant model of breast cancer. The aim of our research has been to dissect the mechanisms of CD8⁺ T cell tolerance in this mouse model. Knowledge of the mechanisms of tolerance in these mice will lead to the development of more effective vaccine strategies that can overcome tolerance to the *neu* antigen.

We identified RNEU₄₂₀₋₄₂₉ as the immunodominant epitope in rat *neu*, and that *neu*-N mice given vaccine alone develop low-avidity CTL specific for this peptide as compared with CTL from FVB/N mice. However, if vaccine is combined with immunomodulatory chemotherapy in *neu*-N mice, high avidity CTL specific for RNEU₄₂₀₋₄₂₉ are now generated. Importantly, the CTL are not only high avidity, but they are also able to eradicate tumor in the *neu*-N mice. Our research has focused on why these high avidity T cells can be activated only when vaccine is combined with chemotherapy and how the immune system prevents their activation when vaccine alone is given. We have shown that T_{regs} are an important target of the chemotherapy and that they are able to suppress the antitumor response *neu*-N mice. We have also shown that other, as yet undetermined, mechanisms of tolerance also play a role in the *neu*-N mice.

Our work in the *neu*-N mouse model with combining vaccine and chemotherapy is the impetus behind a new clinical trial at our institution. Dr. Leisha Emens is currently enrolling patients on a trial combining a GM-CSF-secreting breast cancer vaccine with immunomodulatory doses of Cy and Dox. Along with clinical outcomes, blood samples are being taken to allow for the study of how the vaccine is working in humans. The findings of this trial will greatly enhance our understanding of immune tolerance to tumor antigens in humans and if chemotherapy is able to break tolerance similar to our observations in the *neu*-N mice.

Cancer vaccines alone have shown promise in treating cancer. However, great improvements in the efficacy of these vaccines are needed. Our work provides several critical insights into what approaches might be taken to improve the vaccines. First, we have shown that vaccine alone is not enough. Even though the vaccine is effective in a non-tolerant host, mechanisms of tolerance will prevent the activation of the most potent CTL in a tolerant host. Second, contrary to other reports, high avidity, tumor reactive T cells can persist in a tolerant host, yet they will not be activated if vaccine alone is given. And third, T_{regs} represent promising targets that can be manipulated to allow the high avidity, tumor reactive CTL to be activated. Our future research will continue to focus on the mechanisms of tolerance in the *neu*-N mice with the goal of creating vaccine approaches that will activate the high avidity CTL that are most effective at eradicating tumor.

References

1. Disis, M. L. and Cheever, M. A. HER-2/*neu* protein: a target for antigen-specific immunotherapy of human cancer. *Adv Cancer Res.* 1997, 71: 343-71.
2. Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., and Muller, W. J. Expression of the *neu* protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. *Proc Natl Acad Sci U S A.* 1992, 89: 10578-82.

3. Reilly, R. T., Gottlieb, M. B., Ercolini, A. M., Machiels, J. P., Kane, C. E., Okoye, F. I., Muller, W. J., Dixon, K. H., and Jaffee, E. M. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. *Cancer Res.* 2000, 60: 3569-76.
4. Pinilla C., Rubio-Godoy V., Dutoit V., Guillaume P., Simon R., Zhao Y., Houghten R.A., Cerottini J.C., Romero P., Valmori D. Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes. *Cancer Res.* 2001, Jul 1;61(13):5153-60.
5. Schneck, J.P. Monitoring antigen-specific T cells using MHC-Ig dimers. *Immunol. Invest.* 2000, 29:163-9.
6. Slansky, J. E., F. M. Rattis, L. F. Boyd, T. Fahmy, E. M. Jaffee, J. P. Schneck, D. H. Margulies, and D. M. Pardoll. 2000. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. *Immunity* 13:529.
7. Kreuwel H.T., Sherman L.A. The T-cell repertoire available for recognition of self-antigens. *Curr. Opin. Immunol.* 2001, Dec;13(6):639-43.
8. Machiels J.P., Reilly R.T., Emens L.A., Ercolini A.M., Lei R.Y., Weintraub D., Okoye F.I., Jaffee E.M. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. *Cancer Res.* 2001, May 1;61(9):3689-97.
9. Sakaguchi S. Naturally arising CD4⁺ regulatory t cells for immunologic self-tolerance and negative control of immune responses. *Annu. Rev. Immunol.* 2004;22:531-62.
10. Takahashi T., Tagami T., Yamazaki S., Uede T., Shimizu J., Sakaguchi N., Mak T.W., Sakaguchi S. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. *J. Exp. Med.* 2000, Jul 17;192(2):303-10.
11. Hoffmann, T. K., D. J. Loftus, K. Nakano, M. J. Maeurer, K. Chikamatsu, E. Appella, T. L. Whiteside, and A. B. DeLeo. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope. *J. Immunol.*, 2002, 168:1338

Identification and Characterization of the Immunodominant Rat HER-2/neu MHC Class I Epitope Presented by Spontaneous Mammary Tumors from HER-2/neu-Transgenic Mice¹

Anne M. Ercolini, Jean-Pascal H. Machiels,² Yi Cheng Chen, Jill E. Slansky,³ Martin Giedlen,⁴ R. Todd Reilly, and Elizabeth M. Jaffee⁵

The HER-2/neu (*neu-N*)-transgenic mice are a clinically relevant model of breast cancer. They are derived from the parental FVB/N mouse strain and are transgenic for the rat form of the proto-oncogene HER-2/neu (*neu*). In this study, we report the identification of a MHC class I peptide in the neu protein that is recognized by CD8⁺ T cells derived from vaccinated FVB/N mice. This 10-mer was recognized by all tumor-specific FVB/N T cells generated regardless of the TCR V β region expressed by the T cell or the method of vaccination used, establishing it as the immunodominant MHC class I epitope in neu. T cells specific for this epitope were able to cure FVB/N mice of transplanted neu-expressing tumor cells, demonstrating that this is a naturally processed peptide. Altered peptide analogs of the epitope were analyzed for immunogenicity. Vaccination with dendritic cells pulsed with a heteroclitic peptide provided FVB/N and *neu-N* mice with increased protection against tumor challenge as compared with mice immunized with dendritic cells loaded with either wild-type or irrelevant peptide. Discovery of this epitope allows for better characterization of the CD8⁺ T cell responses in the *neu-N* mouse model in which neu-specific tolerance must be overcome to produce effective antitumor immunity. *The Journal of Immunology*, 2003, 170: 4273–4280.

An important role for Ag-specific CD8⁺ CTLs in antitumor immunity has been demonstrated in both murine tumor models and cancer patients. In mice, immunization with model and naturally expressed tumor Ags or their MHC class I (MHC-I)⁶ epitopes induces antitumor CTL that mediate in vivo tumor rejection (1–12). Patients with established disease have shown some response when given adoptively transferred tumor-specific CTL (13–15). Similarly, clinical trials testing the efficacy of immunizing with MHC-I tumor epitopes from the human pap-

illoma virus Ag E7 have resulted in T cell responses in some patients with cervical cancer (16–18). Several trials undertaken with peptides derived from melanoma-associated Ags have resulted in the induction and expansion of Ag-specific CTL. In some cases, immunization was also associated with clinical responses (19–22). However, in the majority of patients, immunization with MHC-I peptides induces T cell responses that are weak and ineffective in inducing significant tumor regression. As with all cancer therapies, the application of spontaneously arising mouse cancer models is central to the development of enhanced immunotherapies for human cancer (23).

We previously described *neu-N*-transgenic mice as a model of breast cancer that closely mimics immune tolerance described in some patients with cancer (24). These mice, derived from the parental FVB/N strain, express the wild-type rat HER-2/neu (*neu*) cDNA under the control of a mouse mammary tumor virus promoter (25). Female mice spontaneously and stochastically develop mammary tumors beginning at 4 mo of age. Mammary glands that have become tumorigenic overexpress the *neu* transgene relative to *neu* expression in normal glands in the same mice. Because the neu tumor Ag is endogenous to the host, this allows for the development of tolerance to the Ag, as evidenced by the poor ability of these mice to develop neu-specific antitumor immunity following vaccination as compared with the parental FVB/N mice. In the parental strain, depletion of CD8⁺ T cells before neu-specific vaccination inhibits their ability to reject a subsequent tumor challenge (24). Similarly, depletion of CD8⁺ T cells in transgenic mice before vaccination accelerates tumor outgrowth (26–29). However, unlike the parental mice, the transgenic mice are rarely cured of neu-expressing tumors. These data suggest that neu-specific CTL in *neu-N* mice are either weak lytic agents or are actively tolerated, either through deletion or anergy induction among high-avidity T cells.

The current study was designed to identify epitopes expressed by the rat neu and recognized by FVB/N (H-2^d)-derived CTL.

Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins, Graduate Program in Immunology, The Johns Hopkins School of Medicine, Baltimore, MD 21231

Received for publication July 18, 2002. Accepted for publication February 13, 2003.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by National Institutes of Health/National Cancer Institute National Cooperative Drug Discovery Group Grant 2U19CA72108 (to E.M.J.), Specialized Programs of Research Excellence in Breast Cancer Grant 1P50CA88843-01 (to E.M.J.), Breast Cancer Research Foundation Grant (to E.M.J.), American Cancer Society Research Scholar Grant RSG-01-080-01-LIB (to R.T.R.), Susan G. Komen Foundation Grant BCTR00-00068 (to R.T.R.), National Institutes of Health Grant CA76669 (to J.E.S.), Cancer Research Institute Grant 311-2007 (to A.M.E.), National Institutes of Health/National Institute of Allergy and Infectious Diseases Grant 5T32AI07247-21 (to A.M.E.), and Department of Defense Grant DAMD17-01-1-0282 (to A.M.E.). J.P.M. is a Fulbright Scholar supported by a grant from Belgium Televisie-Fonds National de la Recherche Scientifique (credit 7.4568.98) and Oeuvre Belge du Cancer.

² Current address: Laboratoire d'Oncologie Experimentale, Avenue Hippocrate, 54, UCL 5471, Tour Claude Bernard 4-ieme Etage, B-1200 Brussels, Belgium.

³ Current address: Integrated Department of Immunology, National Jewish Medical and Research Center, 1400 Jackson Street, Room K511a, Denver, CO 80206.

⁴ Current address: Cerus Corporation, 2411 Stanwell Drive, Concord, CA 94520.

⁵ Address correspondence and reprint requests to Dr. Elizabeth Jaffee, Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building 4 M07, 1650 Orleans Street, Baltimore, MD 21231. E-mail address: ejaffee@jhmi.edu

⁶ Abbreviations used in this paper: MHC-I, MHC class I; HA, hemagglutinin; ICS, intracellular cytokine staining.

Identification and characterization of these epitopes are critical to understanding the difference in neu-reactive T cell responses between the transgenic and parental mice. Numerous tolerance studies have shown that T cells reactive with endogenous Ags expressed in the thymus are deleted (30–33), although some T cells can escape and exist in the periphery in a functionally unresponsive state (30, 34, 35). Similarly, T cells reactive with endogenous Ags not expressed in the thymus may be deleted or rendered nonresponsive in the periphery (36–38). Knowledge of the MHC-I epitopes in neu will allow us to study the fate of T cell responses directed at these epitopes in the neu-N-transgenic tolerant mice. In addition, it may be possible to alter these epitopes to identify heteroclitic epitopes with improved immunogenicity in the transgenic mice.

We have identified the immunodominant MHC-I epitope in the rat neu protein. This peptide is recognized by all neu-specific T cell lines and clones we derived from the splenocytes of vaccinated FVB/N mice, regardless of the TCR V β region expressed. In addition, we show that adoptive transfer of T cells specific for this peptide is protective in vivo. Furthermore, immunization with a heteroclitic version of this peptide is also protective against challenge with mammary tumors expressing the naturally processed epitope.

Materials and Methods

Peptides and primers

A panel of 135 peptides from fragment 4 (see Fig. 2) used in the initial screening were synthesized by Chiron (Emeryville, CA). All other peptides (>95% purity) were from the Johns Hopkins Biosynthesis and Sequence Facility (Department of Biochemistry, Johns Hopkins School of Medicine, Baltimore, MD). The PCR primers used to create the neu fragments (see Fig. 1) are as follows: fragment 1 (bp 1–508), 5'-CCGGGCCGAATTC GCAATGATC and 3'-CCCCGAATTCCTACTGAGGGTTCACCGGATCAA; fragment 2 (bp 458–886), 5'-GACATGAAGTTGCGGCTCC TAGTCTCACAGAGATCCTGAAG and 3'-CCCCGAATTCCTACTC AGGGTTGTGATCGGACTC; fragment 3 (bp 836–1294), 5'-GACATGA AGTTGCGGCTCCCTCGTCACCTACAACACA and 3'-CCCC GAATTCCTAGAGGTACCGGAGACTGTCTGG; fragment 4 (bp 1244–1675), 5'-GACATGAAGTTGCGGCTCCCTATCACAGGTTAAGTGTATC and 3'-CCCCGAATTCCTACTTCCATACTCGGCACTCCTC; fragment 5 (bp 1607–2077), 5'-GACATGAAGTTGCGGCTCCCTAC CCAGTGTGTCAACTGCAGT and 3'-CCCCGGTACCCTAGATCTTC TGTCTCCTTCGTTT; fragment 6 (bp 2009–2476), 5'-GACATGAAGT TGCGGCTCCCTGGCGTCTGCTGTTCTGATC and 3'-CCCCGGTA CCCTAACCTCGGTGTCTCGGACATG; fragment 7 (bp 2405–2872), 5'-GACATGAAGTTGCGGCTCCCTTCCACAGTACAGCTGGTGACA and 3'-CCCCGGTACCCTAGCAGATTGGAGGCTGAGGTAG; fragment 8 (bp 2801–3271), 5'-GACATGAAGTTGCGGCTCCCTGATGG AATCCAGCCCGGGAG and 3'-CCCCGGTACCCTACCCTTCC GAGGGAGCCAGTGG; and fragment 9 (bp 3203–3796), 5'-GACATGAAGTTGCGGCTCCCTGAGCTGACACTGGGCTGGAG and 3'-CCCCGGTACCCTATACAGGTACCTCCAGGCCTAG. Each fragment was ligated into the pcDNA3.1 mammalian transfection vector (Invitrogen, Carlsbad, CA) at the multicloning site.

Cell lines and medium

The IT22 cell line derives from a spontaneously transformed mouse fibroblast line as described previously (39). NIH 3T3 cells are a mouse fibroblast line (ATCC CRL-1658; American Type Culture Collection (ATCC), Manassas, VA). Rat neu cDNA was cloned from pSV2-neu-N (40) and ligated into the pcDNA3.1 vector (Invitrogen). IT22 cells were transfected with this construct by electroporation (20 μ g/10⁷ cells) to produce IT22neu cells. The human B7-1 gene was retrovirally inserted into rat neu-expressing NIH 3T3 cells (3T3neu; ATCC CRL-1915) using previously described methods (41) to produce 3T3neuB7-1 cells. The same neu-expressing NIH 3T3 cells were transduced with a murine GM-CSF retrovirus using the same methods for inserting the B7-1 gene to create 3T3neuGM vaccine cells. L-D^a cells and L-L^a cells are murine fibroblast cell lines transfected with murine H-2D^a or -L^a, respectively (42). All of the above cell lines were maintained at 37°C and 10% CO₂ in DMEM (Life Technologies, Rockville, MD) supplemented with 10% bovine calf serum (HyClone, Logan, UT), 1% L-glutamine (JRH Biosciences, Lenexa, KS), 1% nonessential amino acids (Sigma-Aldrich, St. Louis, MO), 1% sodium pyruvate (Sigma-Aldrich), and 0.5% penicillin/streptomycin (Sigma-Aldrich). The NT2 and

NT5B7-1 neu-expressing tumor lines are derived from spontaneous mammary tumors excised from the neu-N mice as previously described (24, 43).

Cloning and transfection of H-2D^a

Murine H-2D^a was cloned from the L-D^a cell line (5' primer, ATGGCTC CGCGCAGCTGCT; 3' primer, TCACGCTTTACAATCTCGGA) and ligated into pcDNA3.1. The T2 cell line is a B lymphoblast/T lymphoblast hybrid human cell line deficient in the MHC-I TAP transporter molecule (ATCC CRL-1992). These cells were transfected with D^a by electroporation (20 μ g/1 $\times$ 10⁷ cells) to create the T2D^a cell line. T2D^a cells were maintained at 37°C and 5% CO₂ in RPMI 1640 (Life Technologies) supplemented with 10% FBS (HyClone), 1% L-glutamine, 1% nonessential amino acids, 1% sodium pyruvate, and 0.5% penicillin/streptomycin.

neu-specific T cell lines and clones and hemagglutinin (HA)-specific T cell line

Some CD8⁺ T cell lines were derived from FVB/N mice that were s.c. vaccinated with 1 $\times$ 10⁶ irradiated 3T3neuGM cells at each of three sites (two forelimbs and one hindlimb). Mice were sacrificed, and spleens were excised 2 wk later. Splenocyte cultures were initially stimulated every 5 days with irradiated, IFN- γ -treated NT5B7-1 cells and then every 9 days by the addition of irradiated 3T3neuB7-1 cells as stimulators and FVB/N-derived splenocytes as feeders. Clones were developed from this line by limiting dilution. Other CD8⁺ T cell lines were produced from the splenocytes of mice vaccinated with a neu-expressing recombinant vaccinia or neu plasmid DNA as described previously (24). A T cell line specific for the irrelevant Ag HA was derived from mice vaccinated with HA recombinant vaccinia virus as described previously (44). T cells were maintained at 37°C and 5% CO₂ in CTL medium (RPMI 1640 supplemented with 10% FBS, 1% L-glutamine, 0.1% 2-ME (Sigma-Aldrich), and 0.5% penicillin/streptomycin) supplemented with 10 cetus U/ml murine IL-2 (supernatant from B16 IL-2 line (45)).

Chromium release assays

Lysis assays were performed in triplicate in 96-well V-bottom plates as previously described (24). Briefly, target cells were resuspended in 100 μ l of CTL medium and labeled with 0.2 mCi of ⁵¹Cr/2 $\times$ 10⁶ cells at 37°C and 5% CO₂ for 1 h. Cells were washed in CTL medium and resuspended at 6 $\times$ 10⁴ cells/ml in RPMI 1640. To pulse peptide onto targets, 100 μ l of peptide in RPMI 1640 was added to 50- μ l targets for 1 h at room temperature in each well. After the removal of 100 μ l of supernatant, 150 μ l of T cells in CTL medium was added for the indicated E:T ratio. After a 4-h incubation, 100 μ l of supernatant was assayed for ⁵¹Cr release and percent specific lysis was determined by the formula: ((⁵¹Cr release sample – spontaneous ⁵¹Cr release target alone)/(maximum ⁵¹Cr release target alone – spontaneous ⁵¹Cr release target alone) $\times$ 100. For the Ab blocking assays, the H-2D^a Ab 30-5-7S (ATCC HB-31) was added for 30 min at 37°C to 100 μ l of target cells resuspended in CTL medium at a final concentration of 50 μ M before addition of effector T cells.

Development and transfection of neu fragments

Nine overlapping fragments of the neu cDNA were created using specific primers and PCR amplification (Fig. 1A) and then ligated into pcDNA3.1. The fragment constructs were then transfected into NIH 3T3 cells using electroporation (20 μ g/1 $\times$ 10⁷ cells) or Lipofectamine (1.5 μ g/3 $\times$ 10⁵ cells; Life Technologies). Limiting dilution produced several clones of each fragment. RT-PCR was performed using primers described above to determine which clones expressed fragment mRNA.

Mice and dendritic cell immunizations

FVB/N mice were purchased at 6–8 wk of age from the National Cancer Institute (Bethesda, MD). neu-N mice (25) were bred to homozygosity as verified by Southern blot analysis. Splenic dendritic cells were generated from FVB/N mice as previously described (46). On the day of immunization, cells were collected, resuspended at 4 $\times$ 10⁶/ml in AIM-V medium (Life Technologies), and pulsed with 300 μ g/ml peptide for 3 h. Cells were then washed three times in HBSS (pH 7.4) and resuspended at 2 $\times$ 10⁶ cells/ml. Mice were given 0.1 ml s.c. injections in each hindlimb on days 0 and 7 and challenged with NT2 mammary tumor cells in the right hindlimb on day 14.

GM-CSF release ELISA

Peptides were pulsed onto NIH 3T3 cells (which were grown overnight at 26°C to increase the number of empty MHC on the cell surface) in RPMI 1640 at 26°C for 1 h at a final concentration of 0.1 μ M. Targets were then

washed twice in CTL medium, and 1×10^5 T cells were added for a 1:1 E:T ratio. Plates were incubated at 37°C and 5% CO₂ for 24 h, and supernatants were harvested for the ELISA (Endogen, Woburn, MA). For the screening of *neu* fragments, 1×10^5 T cells and 3×10^5 targets were plated in CTL medium for 24 h and an ELISA was performed.

Flow cytometry (FACS)

Cells were stained by washing them two times in FACS buffer (1× HBSS (pH 7.4), 2% FBS, 1% HEPES (Life Technologies), and 0.1% NaN₃ (Sigma-Aldrich)) and incubating with Ab for 20 min at 4°C. Staining of TCR Vβ4, Vβ14, and Vβ17 was done using supernatants from hybridomas KT4-10, 14-2, and KJ23, respectively (47). Abs to Vβ2, -6, and -7, and fluorescence-conjugated secondary Abs were purchased from BD Pharmingen (La Jolla, CA). Ab to CD8 was purified from the 2.43 hybridoma (ATCC HB-27). MHC staining was done using supernatant collected from hybridomas 30-5-7S, 113, and 28-14-8S, which are specific for H-2D^a (42). The secondary Ab for all three Abs was FITC-conjugated goat anti-mouse IgG (BD Pharmingen).

Intracellular cytokine staining (ICS)

ICS was performed as directed using a BD Pharmingen kit for detection of murine IFN-γ. Briefly, 1×10^6 splenocytes (nylon wool purified to deplete B cells and macrophages) were incubated 12–16 h with an equal ratio of indicated targets in the presence of GolgiStop. Cells were washed in FACS buffer and stained with FITC-conjugated Ab to CD8, fixed and permeabilized, and stained with PE-conjugated Ab to IFN-γ.

Results

Generation of *neu*-specific CD8⁺ T cells from vaccinated FVB/N mice

Three T cell lines were generated to characterize the T cell populations that result from different vaccination experiments as well as from different *neu* targeted vaccine approaches shown to be potent in other tumor models (48). A T cell line was therefore generated from mice vaccinated with the 3T3neuGM whole cell vaccine, and 11 *neu*-specific T cell clones were derived from this line. In addition, lines were created from mice vaccinated with the vaccinia vector expressing the entire *neu* protein and from mice vaccinated with *neu* plasmid DNA. All lines and clones were shown to lyse the full-length *neu* protein in a ⁵¹Cr release assay using 3T3neu vs 3T3 wild-type targets (not shown). Analysis of the Vβ usage of these T cell lines and clones suggests that the *neu* CD8⁺ T cell response is oligoclonal. Specifically, TCRs utilizing six Vβ regions (TCR Vβ2, -4, -6, -7, -14, and -17) were identified (data not shown).

Identification of RNEU_{420–429}, a peptide epitope contained in the extracellular domain of the rat *neu* protein, as the T cell target of all FVB/N-derived T cell lines and clones

As an initial approach to roughly map the position of *neu* epitopes, the *neu* cDNA was divided into nine approximately equal fragments overlapping by 15–25 aa (Fig. 1A). NIH 3T3 cells were




FIGURE 1. Extracellular fragment 4 of *neu* contains a *neu* MHC-I epitope recognized by the FVB/N-derived T cell clones. **A**, Nine overlapping fragments of *neu* cDNA were created using specific primers and PCR amplification. The numbers under each fragment refer to the starting and ending base pair within the entire *neu* cDNA. Each fragment was sequenced and confirmed to be the original rat *neu* sequence before ligation into the vector pcDNA3.1. The fragments were then transfected into 3T3 cells for use as targets in T cell assays. T cells (1×10^5) and 3×10^5 targets were plated in duplicate in 96-well plates and incubated at 37°C for 24 h. Supernatants were collected and tested for levels of GM-CSF by ELISA. Data are shown as degree of color change (OD). Effectors were FVB/N Vβ4A clone (TCR Vβ4) (**B**) and FVB/N Vβ6A clone (TCR Vβ6) and FVB/N Vβ14A clone (TCR Vβ14) (**C**). T cells show recognition of full-length *neu* (■) and of fragment 4 (▨).




FIGURE 2. The original identified 10-mer RNEU₄₂₀₋₄₂₉ is the optimal epitope recognized by neu-specific T cell clones. Full-length and truncated versions of the epitope (as well as the irrelevant lymphocytic choriomeningitis virus nucleoprotein peptide NP₁₁₈₋₁₂₆ (68)) were pulsed onto 3×10^3 chromium-labeled IT22 cells for 1 h at 37°C. T cells were added before a 4-h incubation at 37°C. E:T ratios ranged from 15:1 to 25:1. Effectors were FVB/N Vβ2A clone (Vβ2) (A), FVB/N Vβ4A clone (Vβ4) (B), FVB/N Vβ6A clone (Vβ6) (C), and FVB/N Vβ14A clone (Vβ14) (D). *Insets*, Surface staining of T cell clones. Effectors were stained with Ab to CD8 (thin line), Ab to appropriate TCR Vβ region (thick line), or the irrelevant Ab rat IgG (dotted line).

transfected with these constructs and used as targets in GM-CSF release assays to identify which fragment contained the peptide(s) recognized by the clones. Fig. 1B shows recognition of 3T3 cells expressing fragment 4 (aa 410–553) by the FVB/N-derived T cell clone FVB/N Vβ4A (expressing TCR Vβ4). Recognition of fragment 4 was also seen with FVB/N Vβ6A clone (TCR Vβ6) and FVB/N Vβ14A clone (TCR Vβ14) (Fig. 1C). This fragment is located in the extracellular domain of neu near the transmembrane region.

Peptides 10 aa in length were synthesized, and these peptides spanned the entire sequence of fragment 4 (excluding the overlapping regions with fragments 3 and 5) and overlapped by nine residues each. Of the 135 peptides made, one (RNEU₄₂₀₋₄₂₉) was consistently recognized by clones in GM-CSF release ELISA (data not shown). This peptide (PDSLRDLSVF), along with its 8- and 9-aa derivatives, was synthesized and tested for recognition by neu-specific T cells in Cr⁵¹ release lysis assays. As shown in Fig. 2, the 10-mer was recognized more efficiently than the shorter peptides regardless of the TCR Vβ region expressed by the T cell. This peptide was subsequently found to be recognized by all T cell lines and clones derived, suggesting that RNEU₄₂₀₋₄₂₉ is the immunodominant MHC-I neu epitope recognized by FVB/N-derived T cells. To further analyze the CD8⁺ T cell response to neu in FVB/N mice, frequency analysis was performed on the spleens of five individual mice given a s.c. 3T3neuGM vaccine. Fourteen days after vaccination, spleens were excised and cultured with 3T3neuB7-1 cells for 7 days before performing ICS to determine the response to full-length neu and to RNEU₄₂₀₋₄₂₉. As shown in

Table I, all vaccinated FVB/N mice developed CD8⁺ T cells that were specific for both full-length neu and for RNEU₄₂₀₋₄₂₉. This further supports the immunodominance of RNEU₄₂₀₋₄₂₉ in

Table I. T cell specificity of vaccinated FVB/N and neu-N mice^a

Mouse No.	% neu Specific ^b	% RNEU ₄₂₀₋₄₂₉ Specific ^c
FVB/N 1	1.83	2.48
FVB/N 2	0.88	1.92
FVB/N 3	1.47	2.75
FVB/N 4	0.06	0.48
FVB/N 5	0.28	1.16
neu-N 1	0.00	0.32
neu-N 2	0.13	0.22
neu-N 3	0.00	0.23
neu-N 4	0.00	0.00
neu-N 5	0.02	0.26
neu-N 6	0.00	0.07
neu-N 7	0.00	0.06
neu-N 8	0.16	0.00
neu-N 9	0.00	0.04
neu-N 10	0.14	0.00

^a Specificity determined by the percentage of CD8⁺ splenocytes staining positive for IFN-γ in response to target in ICS assay.

^b neu specificity determined by the percentage responding to IT22neu minus the percentage responding to IT22.

^c RNEU₄₂₀₋₄₂₉ specificity determined by the percentage responding to T2D^a cells pulsed with RNEU₄₂₀₋₄₂₉ minus the percentage responding to T2D^a cells pulsed with the irrelevant peptide NP₁₁₈₋₁₂₆.




FIGURE 3. H-2D^a is the restricting MHC molecule for the recognition of RNEU₄₂₀₋₄₂₉ by FVB/N T cell clones. T2 cells were transfected via electroporation (20 μ g/10⁷ cells) with D^a cDNA to create T2D^a cells. Chromium-labeled T2D^a cells (3×10^3) were pulsed for 1 h with either RNEU₄₂₀₋₄₂₉ or the heteroclitic variant RNEU₄₂₀₋₄₂₉A2. T cells (3×10^4) were then incubated with the targets for 4 h at 37°C. Effectors were FVB/N Vβ2A clone (Vβ2) (A), FVB/N Vβ4A clone (Vβ4) (B), FVB/N Vβ6A clone (Vβ6) (C), and FVB/N Vβ14A clone (Vβ14) (D). T cell clone FVB/N Vβ4A demonstrates enhanced lysis of the RNEU₄₂₀₋₄₂₉ peptide with an alanine substituted at position 2 (RNEU₄₂₀₋₄₂₉A2). E, T2D^a cells were incubated with Ab to D^a (28-14-8S) followed by FITC-conjugated Ab to mouse IgG (thick line) to confirm surface expression of the MHC molecule (thin line, secondary Ab alone).

FVB/N mice. The same analysis was done on the spleens of 10 individual *neu*-N mice given the same vaccine. As shown in Table I, the tolerized *neu*-N mice do not demonstrate appreciable T cell activity for the immunodominant epitope.

H-2D^a is the restriction element for RNEU₄₂₀₋₄₂₉

Initial CTL blocking studies using an Ab specific for H-2D^a and -L^a (30-5-7S) indicated that lysis of *neu* was restricted to one of these two molecules. MHC restriction was further determined by pulsing RNEU₄₂₀₋₄₂₉ onto mouse L cells that were transfected with either H-2D^a or -L^a. FVB/N Vβ4A clone cells lysed targets transfected with D^a but not those transfected with L^a (data not shown). The D^a molecule was then cloned and transfected into T2 cells. When pulsed with RNEU₄₂₀₋₄₂₉, T2D^a cells were recognized in a ⁵¹Cr release assay by all FVB/N-derived T cell lines and clones. Lysis of T2D^a cells pulsed with decreasing concentrations of the RNEU₄₂₀₋₄₂₉ peptide is shown in Fig. 3 for the four T cell clones also evaluated in Fig. 2. These data established D^a as the restricting MHC-I molecule for RNEU₄₂₀₋₄₂₉.

Adoptive transfer of RNEU₄₂₀₋₄₂₉-specific T cells into tumor-bearing FVB/N mice confirms that this peptide is a tumor rejection epitope naturally expressed by mammary tumor cells *in vivo*

FVB/N mice were given a s.c. leg injection of *neu*-expressing tumor cells (NT2) followed 1 day later by i.v. transfer of an FVB/N T cell line (derived from mice given *neu* plasmid vaccine) specific for RNEU₄₂₀₋₄₂₉. This line was chosen because it demonstrated the highest lysis of NT2 cells *in vitro*. As shown in Fig. 4, mice receiving these T cells showed protection from tumor outgrowth as

compared with mice receiving a control T cell line specific for the irrelevant Ag HA ($p < 0.0008$). This experiment was repeated using several RNEU₄₂₀₋₄₂₉ specific T cell clones and lines with similar results.




FIGURE 4. Confirmation that RNEU₄₂₀₋₄₂₉ is the naturally processed mammary tumor epitope expressed *in vivo*. FVB/N mice (9–10 mice/group) were given a s.c. leg injection of 5×10^6 *neu*-expressing tumor cells (NT2 cells derived from spontaneously arising mammary tumors in *neu*-N mice). One day later, mice were given an i.v. transfer of 1×10^7 CD8⁺ T cells specific for either RNEU₄₂₀₋₄₂₉ or for the irrelevant Ag HA. Mice were observed twice a week for the development of tumor in the leg. Additional independent studies were performed with other T cell clones and lines with similar results.




FIGURE 5. Mice immunized with the alanine substituted variant of RNEU₄₂₀₋₄₂₉ show a lag in neu-expressing tumor growth as compared with immunization with wild-type RNEU₄₂₀₋₄₂₉ or the irrelevant peptide. Splenic dendritic cells generated from FVB/N mice were pulsed with 300 μ g/ml either RNEU₄₂₀₋₄₂₉, RNEU₄₂₀₋₄₂₉A2, or the lymphocytic choriomeningitis virus NP₁₁₈₋₁₂₆ peptide. Subcutaneous injections (0.1 ml) of 2×10^5 cells were given in each hindlimb on days 0 and 7. Mice were challenged s.c. with NT2 tumor cells on day 14. *A*, FVB/N mice (19–20/group) were given 5×10^6 NT2 cells. *B*, neu-N mice (10/group) were given 5×10^4 NT2 cells. Mice were followed twice per week for development of leg tumor.

Identification of a heteroclitic peptide of RNEU₄₂₀₋₄₂₉ that can immunize mice in vivo against outgrowth by the mammary tumor

Identification of the immunodominant neu peptide allowed us to search for altered peptide analogs with potentially enhanced immunogenicity. Altered forms of RNEU₄₂₀₋₄₂₉ were created by substituting alanine at each of the 10 positions. This type of approach has been successful in identifying heteroclitic T cell peptides in both rodent and human settings (6, 49–54). In the majority of cases, substitutions did not enhance recognition. However, when alanine was substituted for glutamate at position 2, this peptide (designated RNEU₄₂₀₋₄₂₉A2) demonstrated markedly improved recognition by the T cell clone FVB/N V β 4A in a lysis assay as compared with wild-type peptide (Fig. 3). Interestingly, the heteroclitic peptide was found to have a lower binding affinity than the wild-type RNEU₄₂₀₋₄₂₉ peptide in a T2D^a MHC stabilization assay (data not shown), suggesting that its improved stimulatory capacity was instead due to the enhanced stability of the TCR/MHC/peptide complex.

To determine whether this heteroclitic peptide can immunize mice against mammary tumor expressing the natural RNEU₄₂₀₋₄₂₉ epitope, both wild-type RNEU₄₂₀₋₄₂₉ and the heteroclitic variant RNEU₄₂₀₋₄₂₉A2 were used to vaccinate mice. Dendritic cells derived from FVB/N mice were pulsed in vitro with either of these peptides (or with an irrelevant peptide) and then injected s.c. into FVB/N and neu-N mice followed by a s.c. NT2 tumor challenge. As shown in Fig. 5, mice immunized with dendritic cells pulsed with the wild-type peptide developed tumor at about the same rate as mice immunized with an irrelevant peptide ($p < 0.15$ for FVB/N mice; $p < 0.39$ for neu-N mice). However, FVB/N mice immunized with the heteroclitic peptide showed a lag in tumor growth as compared with FVB/N mice immunized with the irrelevant peptide ($p < 0.012$). Although not statistically significant, neu-N mice demonstrated a promising trend toward protection when vaccinated with the heteroclitic peptide ($p < 0.21$).

Discussion

We have identified a MHC-I epitope in rat HER-2/neu, RNEU₄₂₀₋₄₂₉, which is the dominant target of the CD8⁺ T cell response in FVB/N mice. This peptide, which is contained in the extracellular region of neu, is recognized by all neu-specific CD8⁺ T cell lines and clones derived from vaccinated FVB/N mice regardless of the neu-targeted vaccine approach used for immunization. This was true even though vaccination induced an oligoclonal neu-specific T cell response as determined by the panel of

T cell lines and clones tested expressing several different TCR V β types. This was unexpected because the neu gene is 4kB in size and encodes for a large protein. However, other studies have reported similar findings demonstrating that a single viral or tumor antigenic epitope is recognized by a panel of T cells derived from immunized mice (8, 55–57). In contrast, neu-specific T cells isolated from patients with neu-expressing breast and ovarian cancer typically recognize multiple epitopes in both the extracellular and intracellular domains of the protein (58–63). Therefore, our data suggest that the FVB/N nontolerized mice recognize neu as a foreign Ag.

FVB/N mice were protected against inoculation with a neu-expressing in vitro tumor line (derived from naturally arising mammary tumors in neu-N mice) when T cells specific for this epitope were adoptively transferred. This indicates that RNEU₄₂₀₋₄₂₉ is the immunodominant MHC-I epitope in rat neu that serves as the naturally expressed tumor rejection target on spontaneously arising neu-expressing tumors. It is interesting to note that RNEU₄₂₀₋₄₂₉ differs from the corresponding murine amino acid sequence by 3 aa (64). Furthermore, RNEU₄₂₀₋₄₂₉ specific T cells do not recognize the murine peptide in a ⁵¹Cr release lysis assay (data not shown). This probably explains its high degree of immunogenicity in the FVB/N mice.

Vaccination with the RNEU₄₂₀₋₄₂₉ peptide pulsed onto dendritic cells did not demonstrate antitumor immunity. This is not surprising, because vaccinating mice or patients with solely MHC-I tumor epitopes has produced only modest results in most studies. For some Ags, altering the wild-type MHC-I epitope so that it binds more strongly to MHC or demonstrates greater recognition in vitro by Ag-specific T cells improves the immunization potential and the clinical outcome (54, 65–67). In this study, we show that vaccinating FVB/N mice with dendritic cells pulsed with a heteroclitic variant of the wild-type epitope also induces improved protection against tumors that express the natural RNEU₄₂₀₋₄₂₉ epitope as compared with immunization with the RNEU₄₂₀₋₄₂₉ epitope itself. neu-N mice show a promising trend toward protection when vaccinated with the heteroclitic peptide but not to the degree seen in FVB/N mice. This may reflect the neu-specific tolerance seen in neu-N mice. In any case, this regimen proved to be far less efficacious for either strain of mice than our whole-cell vaccine, further supporting the concept that vaccines that induce both CTL and Th cell responses may be more effective than vaccines that only enhance the CTL response (41, 48).

Few studies have been published dissecting the immune responses in *neu-N* mice, which are transgenic for rat *neu* and therefore express a tissue-specific tumor Ag (24, 26–29, 44). We have previously shown that these mice are tolerant to their transgene as compared with the FVB/N strain from which they were derived and that this tolerance is found both in the humoral and T cell arms of the immune response (24). However, we do not yet know the mechanism of this tolerance. It appears from our studies that *neu-N* mice given a whole-cell 3T3neuGM vaccine do not develop T cells specific for the immunodominant peptide in *neu*, although mice vaccinated with the heteroclitic version of the peptide show a degree of protection from *neu*-expressing tumor challenge. This may indicate that, although the predominant response to *neu* in *neu-N* mice is to other, less immunogenic epitopes, T cells specific for the immunodominant peptide may be induced. However, *neu-N* mouse-derived T cells may recognize the immunodominant epitope with a lower avidity as compared with FVB/N-derived T cells. This tolerance may occur in the thymus, in the periphery, or in both compartments. The identification of RNEU_{420–429} as the immunodominant epitope contained in the rat *neu* protein will facilitate the further characterization of vaccine-induced immune responses in the rat *neu*-transgenic mouse model. To that end, an MHC/peptide tetramer can be made to identify T cells specific for the immunodominant epitope, because it is known that the restricting MHC molecule is H-2D^d. Identification of other epitopes in rat *neu* is also ongoing.

Acknowledgments

We thank David Woodland for providing TCR Abs, Ted Hansen for providing MHC Abs and L-D^d and L-L^d cells, Susan Ivie for dendritic cell culture, and Eric Lutz for assistance in cloning the H-2D^d cDNA. We also thank Drs. Drew Pardoll and Leisha Emens for their critiques.

References

- Pan, Z. K., G. Ikonomidis, A. Lazenby, D. Pardoll, and Y. Paterson. 1995. A recombinant *Listeria* monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. *Nat. Med.* 1:471.
- Pan, Z. K., G. Ikonomidis, D. Pardoll, and Y. Paterson. 1995. Regression of established tumours in mice mediated by the oral administration of a recombinant *Listeria monocytogenes* vaccine. *Cancer Res.* 55:4776.
- Bright, R. K., M. H. Shearer, and R. C. Kennedy. 1994. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells: an antibody-based mechanism for tumor immunity. *J. Immunol.* 153:2064.
- Bright, R. K., B. Beames, M. H. Shearer, and R. C. Kennedy. 1996. Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen. *Cancer Res.* 56:1126.
- Schimmbeck, R., W. Bohm, and J. Reimann. 1996. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2^d mice that reject syngeneic tumors. *J. Immunol.* 157:3550.
- Slansky, J. E., F. M. Rattis, L. F. Boyd, T. Fahmy, E. M. Jaffee, J. P. Schneek, D. H. Margulies, and D. M. Pardoll. 2000. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. *Immunity* 13:529.
- Tuting, T., J. Steitz, J. Bruck, A. Gambotto, K. Steinbrink, A. B. DeLeo, P. Robbins, J. Knop, and A. H. Enk. 1999. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. *J. Gene Med.* 1:400.
- Huang, A. Y., P. H. Guldén, A. S. Woods, M. C. Thomas, C. D. Tong, W. Wang, V. H. Engelhard, G. Pasternack, R. Cotter, D. Hunt, et al. 1996. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. *Proc. Natl. Acad. Sci. USA* 93:9730.
- Bloom, M. B., D. Perry-Lalley, P. F. Robbins, Y. Li, M. el-Gamil, S. A. Rosenberg, and J. C. Yang. 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. *J. Exp. Med.* 185:453.
- Bronte, V., E. Apolloni, R. Ronca, P. Zamboni, W. W. Overwijk, D. R. Surman, N. P. Restifo, and P. Zanovello. 2000. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. *Cancer Res.* 60:253.
- Overwijk, W. W., and N. P. Restifo. 2001. Creating therapeutic cancer vaccines: notes from the battlefield. *Trends Immunol.* 22:5.
- Tuting, T., A. Gambotto, A. DeLeo, M. T. Lotze, P. D. Robbins, and W. J. Storkus. 1999. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. *Cancer Gene Ther.* 6:73.
- Mitchell, M. S., D. Darrah, D. Yeung, S. Halpern, A. Wallace, J. Voland, V. Jones, and J. Kan-Mitchell. 2002. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. *J. Clin. Oncol.* 20:1075.
- Rosenberg, S. A., J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. *J. Natl. Cancer Inst.* 86:1159.
- Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. *Proc. Natl. Acad. Sci. USA* 91:6458.
- Alexander, M., M. L. Salgaller, E. Celis, A. Sette, W. A. Barnes, S. A. Rosenberg, and M. A. Steller. 1996. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. *Am. J. Obstet. Gynecol.* 175:1586.
- Steller, M. A., K. J. Gorski, M. Murakami, R. W. Daniel, K. V. Shah, E. Celis, A. Sette, E. L. Trimble, R. C. Park, and F. M. Marincola. 1998. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. *Clin. Cancer Res.* 4:2103.
- van Driel, W. J., M. E. Rensing, G. G. Kenter, R. M. Brandt, E. J. Krul, A. B. van Rossum, E. Schuurung, R. Offringa, T. Bauknecht, A. Tamm-Hermelink, et al. 1999. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. *Eur. J. Cancer* 35:946.
- Jager, E., M. Ringhoffer, H. P. Dienes, M. Arand, J. Karbach, D. Jager, C. Ilsemann, M. Hagedorn, F. Oesch, and A. Knuth. 1996. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. *Int. J. Cancer* 67:54.
- Jager, E., M. Ringhoffer, J. Karbach, M. Arand, F. Oesch, and A. Knuth. 1996. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8⁺ cytotoxic T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. *Int. J. Cancer* 66:470.
- Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dreno, M. H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene *MAGE-3* and presented by HLA-A1. *Int. J. Cancer* 80:219.
- Coulie, P. G., V. Karanikas, D. Colau, C. Lurquin, C. Landry, M. Marchand, T. Dorval, V. Brichard, and T. Boon. 2001. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene *MAGE-3*. *Proc. Natl. Acad. Sci. USA* 98:10290.
- Klausner, R. D. 1999. Studying cancer in the mouse. *Oncogene* 18:5249.
- Reilly, R. T., M. B. Gottlieb, A. M. Ercolini, J. P. Machiels, C. E. Kane, F. I. Okoye, W. J. Muller, K. H. Dixon, and E. M. Jaffee. 2000. HER-2/*neu* is a tumor rejection target in tolerized HER-2/*neu* transgenic mice. *Cancer Res.* 60:3569.
- Guy, C. T., M. A. Webster, M. Schaller, T. J. Parsons, R. D. Cardiff, and W. J. Muller. 1992. Expression of the *neu* protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. *Proc. Natl. Acad. Sci. USA* 89:10578.
- Cefai, D., B. W. Morrison, A. Sckell, L. Favre, M. Balli, M. Leunig, and C. D. Gimmi. 1999. Targeting HER-2/*neu* for active-specific immunotherapy in a mouse model of spontaneous breast cancer. *Int. J. Cancer* 83:393.
- Amici, A., F. M. Venanzi, and A. Conetti. 1998. Genetic immunization against *neu/erbB2* transgenic breast cancer. *Cancer Immunol. Immunother.* 47:183.
- Chen, Y., D. Hu, D. J. Eling, J. Robbins, and T. J. Kipps. 1998. DNA vaccines encoding full-length or truncated *Neu* induce protective immunity against *Neu*-expressing mammary tumors. *Cancer Res.* 58:1965.
- Esserman, L. J., T. Lopez, R. Montes, L. N. Bald, B. M. Fendly, and M. J. Campbell. 1999. Vaccination with the extracellular domain of p185*neu* prevents mammary tumor development in *neu* transgenic mice. *Cancer Immunol. Immunother.* 47:337.
- Kappler, J. W., N. Roehm, and P. Marrack. 1987. T cell tolerance by clonal elimination in the thymus. *Cell* 49:273.
- Nossal, G. J. 1994. Negative selection of lymphocytes. *Cell* 76:229.
- Sprent, J., and S. R. Webb. 1995. Intrathymic and extrathymic clonal deletion of T cells. *Curr. Opin. Immunol.* 7:196.
- Surh, C. D., and J. Sprent. 1994. T-cell apoptosis detected in situ during positive and negative selection in the thymus. *Nature* 372:100.
- Blackman, M., J. Kappler, and P. Marrack. 1990. The role of the T cell receptor in positive and negative selection of developing T cells. *Science* 248:1335.
- Kisielow, P., H. Bluthmann, U. D. Staerz, M. Steinmetz, and H. von Boehmer. 1988. Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4⁺8⁺ thymocytes. *Nature* 333:742.
- Schonrich, G., F. Momburg, M. Malissen, A. M. Schmitt-Verhulst, B. Malissen, G. J. Hammerling, and B. Arnold. 1992. Distinct mechanisms of extrathymic T cell tolerance due to differential expression of self antigen. *Int. Immunol.* 4:581.
- Ramsdell, F., and B. J. Fowlkes. 1992. Maintenance of in vivo tolerance by persistence of antigen. *Science* 257:1130.
- Morahan, G., J. Allison, and J. F. Miller. 1989. Tolerance of class I histocompatibility antigens expressed extrathymically. *Nature* 339:622.
- Godbout, R., B. L. Gallie, and R. A. Phillips. 1984. Characterization of a stable, anchorage-dependent clone obtained from a spontaneously transformed mouse cell line. *In Vitro* 20:479.

40. Bargmann, C. I., M. C. Hung, and R. A. Weinberg. 1986. Multiple independent activations of the *neu* oncogene by a point mutation altering the transmembrane domain of p185. *Cell* 45:649.
41. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. *Proc. Natl. Acad. Sci. USA* 90:3539.
42. Lee, D. R., R. J. Rubocki, W. R. Lie, and T. H. Hansen. 1988. The murine MHC class I genes, *H-2D^b* and *H-2L^d*, are strikingly homologous to each other, *H-2L^d*, and two genes reported to encode tumor-specific antigens. *J. Exp. Med.* 168:1719.
43. Machiels, J. P., R. T. Reilly, L. A. Emens, A. M. Ercolini, R. Y. Lei, D. Weintraub, F. I. Okoye, and E. M. Jaffee. 2001. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. *Cancer Res.* 61:3689.
44. Reilly, R. T., J. P. Machiels, L. A. Emens, A. M. Ercolini, F. I. Okoye, R. Y. Lei, D. Weintraub, and E. M. Jaffee. 2001. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. *Cancer Res.* 61:880.
45. Fearon, E. R., D. M. Pardoll, T. Itaya, P. Golumbek, H. I. Levitsky, J. W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. *Cell* 60:397.
46. Inaba, K., W. J. Swiggard, R. M. Steinman, N. Romani, and G. Sculer. 1998. *Isolation of Dendritic Cells*. Wiley, New York.
47. Deckhut, A. M., W. Allan, A. McMickle, M. Eichelberger, M. A. Blackman, P. C. Doherty, and D. L. Woodland. 1993. Prominent usage of V β 8.3 T cells in the H-2D^b-restricted response to an influenza A virus nucleoprotein epitope. *J. Immunol.* 151:2658.
48. Greten, T. F., and E. M. Jaffee. 1999. Cancer vaccines. *J. Clin. Oncol.* 17:1047.
49. Herman, J., V. Jongeneel, D. Kuznetsov, and P. G. Coulie. 1999. Differences in the recognition by CTL of peptides presented by the HLA-B*4402 and the HLA-B*4403 molecules which differ by a single amino acid. *Tissue Antigens* 53:111.
50. Sun, D., C. Coleclough, R. Ji, X. Hu, and J. N. Whitaker. 1999. Alanine-substituted peptide ligands differ greatly in their ability to activate autoreactive T-cell subsets specific for the wild-type peptide. *J. Neuroimmunol.* 99:105.
51. Talken, B. L., K. R. Schafermeyer, C. W. Bailey, D. R. Lee, and R. W. Hoffman. 2001. T cell epitope mapping of the Smith antigen reveals that highly conserved Smith antigen motifs are the dominant target of T cell immunity in systemic lupus erythematosus. *J. Immunol.* 167:562.
52. Loftus, D. J., P. Squarcina, M. B. Nielsen, C. Geisler, C. Castelli, N. Odum, E. Appella, G. Parmiani, and L. Rivoltini. 1998. Peptides derived from self-proteins as partial agonists and antagonists of human CD8⁺ T-cell clones reactive to melanoma/melanocyte epitope MART1₂₇₋₃₅. *Cancer Res.* 58:2433.
53. Huarte, E., P. Sarobe, J. Lu, N. Casares, J. J. Lasarte, J. Dotor, M. Ruiz, J. Prieto, E. Celis, and F. Borras-Cuesta. 2002. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements. *Clin. Cancer Res.* 8:2336.
54. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. *Nat. Med.* 4:321.
55. Heukamp, L. C., T. van Hall, F. Ossendorp, J. M. Burchell, C. J. Melief, J. Taylor-Papadimitriou, and R. Offringa. 2002. Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope. *J. Immunother.* 25:46.
56. Weidt, G., O. Utermohlen, J. Heukeshoven, F. Lehmann-Grube, and W. Deppert. 1998. Relationship among immunodominance of single CD8⁺ T cell epitopes, virus load, and kinetics of primary antiviral CTL response. *J. Immunol.* 160:2923.
57. Whitton, J. L., A. Tishon, H. Lewicki, J. Gebhard, T. Cook, M. Salvato, E. Joly, and M. B. Oldstone. 1989. Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity. *J. Virol.* 63:4303.
58. Disis, M. L., J. W. Smith, A. E. Murphy, W. Chen, and M. A. Cheever. 1994. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. *Cancer Res.* 54:1071.
59. Disis, M. L., T. A. Gooley, K. Rinn, D. Davis, M. Piepkorn, M. A. Cheever, K. L. Knutson, and K. Schifman. 2002. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. *J. Clin. Oncol.* 20:2624.
60. Fisk, B., B. Chesak, M. S. Pollack, J. T. Wharton, and C. G. Ioannides. 1994. Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. *Cell. Immunol.* 157:415.
61. Ioannides, C. G., B. Fisk, D. Fan, W. E. Biddison, J. T. Wharton, and C. A. O'Brian. 1993. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. *Cell. Immunol.* 151:225.
62. Knutson, K. L., K. Schifman, and M. L. Disis. 2001. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. *J. Clin. Invest.* 107:477.
63. Rongcun, Y., F. Salazar-Onfray, J. Charo, K. J. Malmberg, K. Evrin, H. Maes, K. Kono, C. Hising, M. Petersson, O. Larsson, et al. 1999. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. *J. Immunol.* 163:1037.
64. Nagata, Y., R. Furugen, A. Hiasa, H. Ikeda, N. Ohta, K. Furukawa, H. Nakamura, T. Kanematsu, and H. Shiku. 1997. Peptides derived from a wild-type murine proto-oncogene *c-erbB-2/HER2/neu* can induce CTL and tumor suppression in syngeneic hosts. *J. Immunol.* 159:1336.
65. Hoffmann, T. K., D. J. Loftus, K. Nakano, M. J. Maeurer, K. Chikamatsu, E. Appella, T. L. Whiteside, and A. B. DeLeo. 2002. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53₂₆₄₋₂₇₂ epitope. *J. Immunol.* 168:1338.
66. Fong, L., Y. Hou, A. Rivas, C. Benike, A. Yuen, G. A. Fisher, M. M. Davis, and E. G. Engleman. 2001. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. *Proc. Natl. Acad. Sci. USA* 98:8809.
67. Scardino, A., D. A. Gross, P. Alves, J. L. Schultze, S. Graff-Dubois, O. Faure, S. Tourdot, S. Chouaib, L. M. Nadler, F. A. Lemonnier, et al. 2002. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. *J. Immunol.* 168:5900.
68. Schulz, M., P. Aichele, R. Schneider, T. H. Hansen, R. M. Zinkernagel, and H. Hengartner. 1991. Major histocompatibility complex binding and T cell recognition of a viral nonapeptide containing a minimal tetrapeptide. *Eur. J. Immunol.* 21:1181.